Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). - Girolomoni, Giampiero; Feldman, Steven R.; Egeberg, Alexander; Puig, Luis; Jung, Jinah; Jung, Hojung; Lee, Younju (Journal of Dermatological Treatment, 2024)